Disease · MONDO_0001505
alcoholic hepatitis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. alcoholic hepatitis. Diseases, record MONDO_0001505. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001505
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs39
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| OXANDROLONE | CHEMBL1200436 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| PREDNISOLONE | CHEMBL131 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 9 | Drugs and targets |
| PENTOXIFYLLINE | CHEMBL628 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 1 | Drugs and targets |
| PEGFILGRASTIM | CHEMBL1201568 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 1 | Drugs and targets |
| FILGRASTIM | CHEMBL1201567 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 0 | Drugs and targets |
| LENOGRASTIM | CHEMBL2109128 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 0 | Drugs and targets |
| METHYLPREDNISOLONE | CHEMBL650 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| PREDNISONE | CHEMBL635 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| BETAMETHASONE | CHEMBL632 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets |
1 to 10 of 39
See all 39 drugsTargets49
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 12 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 3 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| IL1B | Interleukin-1 beta | 2 | Interleukin-1 beta inhibitor | Phase 2 | https://conductscience.org/library/genes/3553 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor agonist | Approval | https://conductscience.org/library/genes/367 | Drugs and targets |
| CASP1 | Caspase | 1 | Caspase inhibitor | Phase 2 | https://conductscience.org/library/genes/834 | Drugs and targets |
| CASP10 | Caspase | 1 | Caspase inhibitor | Phase 2 | https://conductscience.org/library/genes/843 | Drugs and targets |
| CASP12 | Caspase | 1 | Caspase inhibitor | Phase 2 | https://conductscience.org/library/genes/100506742 | Drugs and targets |
| CASP14 | Caspase | 1 | Caspase inhibitor | Phase 2 | https://conductscience.org/library/genes/23581 | Drugs and targets |
1 to 10 of 49
See all 49 targetsTrials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04072822 | Trial of Anakinra (Plus Zinc) or Prednisone in Patients With Severe Alcoholic Hepatitis | Phase 2 | 147 | 2023-07-28 | Alcoholic Hepatitis | ANAKINRA, ZINC SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT01809132 | Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis | Phase 2/3 | 104 | 2020-12-10 | Acute Alcoholic Hepatitis | ANAKINRA, PENTOXIFYLLINE, ZINC SULFATE | Its record names the disease | ClinicalTrials.gov |
| NCT02854631 | Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH) | Phase 2 | 104 | 2019-02-06 | Alcoholic Hepatitis (AH) | PREDNISOLONE, SELONSERTIB | Its record names the disease | ClinicalTrials.gov |
| NCT03775109 | IL-1 Signal Inhibition in Alcoholic Hepatitis | Phase 2 | 55 | 2025-03-11 | Alcoholic Hepatitis | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03829683 | Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis | Phase 2 | 20 | 2023-03-21 | Alcoholic Hepatitis, Sepsis | ASCORBIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02039219 | Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH) | Phase 2 | 19 | 2020-01-28 | Alcoholic Hepatitis | OBETICHOLIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT03432260 | A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis | Phase 2 | 19 | 2022-12-14 | Alcoholic Hepatitis | LARSUCOSTEROL | Its record names the disease | ClinicalTrials.gov |
| NCT02655510 | Use of F-652 in Patients With Alcoholic Hepatitis | Phase 1/2 | 18 | 2019-09-09 | Alcoholic Hepatitis | EFLEPEDOCOKIN ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT01912404 | Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy | Phase 2 | 5 | 2016-11-04 | Alcoholic Hepatitis | EMRICASAN | Its record names the disease | ClinicalTrials.gov |
| NCT00205049 | Pentoxifylline for Acute Alcoholic Hepatitis (AAH) | Phase 1 | 4 | 2014-05-13 | Hepatitis, Alcoholic | PENTOXIFYLLINE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Prednisone vs Anakinra and Zinc: deaths from any cause | 12 of 73 | 22 of 74 | 147 | NCT04072822 | Trial comparisons |
| Prednisone vs Anakinra and Zinc: Number of Participants With Infections | 20 of 73 | 23 of 74 | 147 | NCT04072822 | Trial comparisons |
| Prednisone vs Anakinra and Zinc: serious adverse events | 41 of 73 | 49 of 74 | 147 | NCT04072822 | Trial comparisons |
| Selonsertib + Prednisolone vs Placebo + Prednisolone: deaths from any cause | 14 of 50 | 9 of 52 | 102 | NCT02854631 | Trial comparisons |
| Selonsertib + Prednisolone vs Placebo + Prednisolone: serious adverse events | 25 of 50 | 21 of 52 | 102 | NCT02854631 | Trial comparisons |
| Canakinumab vs Placebo: Number of Deaths at Day 90 | 2 of 28 | 2 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Variceal Haemorrhage Over 90 Days | 1 of 28 | 1 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Encephalopathy Over 90 Days | 9 of 28 | 6 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Infection Over 90 Days | 6 of 28 | 8 of 27 | 55 | NCT03775109 | Trial comparisons |
| Canakinumab vs Placebo: Number of Patients With Sepsis Over 90 Days | 1 of 28 | 1 of 27 | 55 | NCT03775109 | Trial comparisons |
1 to 10 of 28
See all 28 comparisons in its trialsPapers from its trials31
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001505
GET https://conductscience.org/api/diseases/v1/MONDO_0001505/drugs?page=2